MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of marketable...
$283,376K
Proceeds from stock
option exercises and...
$242K
Net cash provided by
investing activities
$126,801K
Net cash provided by
financing activities
$83K
Canceled cashflow
$156,575K
Canceled cashflow
$159K
Net increase
(decrease) in cash, cash...
-$13,534K
Canceled cashflow
$126,884K
Stock-based compensation
expense
$15,660K
Other long-term
assets
-$1,072K
Right-of-use operating asset
-$796K
Operating lease
liabilities, current
$560K
Depreciation expense
$216K
Purchases of marketable
securities
$156,575K
Payment of employee tax
obligations related to...
$159K
Net cash used in
operating activities
-$140,418K
Canceled cashflow
$18,304K
Net loss
-$111,866K
Accrued expenses and
other liabilities
-$15,526K
Accounts payable
-$12,007K
Other receivable
$8,105K
Collaboration receivable -
related party
$7,136K
Amortization of discount on
marketable securities
$1,423K
Prepaid expenses and
other current assets
$1,389K
Operating lease
liabilities, non-current
-$975K
Premium on marketable
securities
$295K
Back
Back
Cash Flow
source: myfinsight.com
Sage Therapeutics, Inc. (SAGE)
Sage Therapeutics, Inc. (SAGE)